Emerging Concepts of Guanine Nucleotide-Binding Protein-Coupled Receptor (GPCR) Function and Implications for High Throughput Screening
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Guanine nucleotide binding protein (G protein) coupled receptors (GPCRs) comprise one of the largest families of proteins in the human genome and are a target for 40% of all approved drugs. GPCRs have unique structural motifs that allow them to interact with a wide and diverse series of extracellular ligands, as well as intracellular proteins, G proteins, receptor activity-modifying proteins, arrestins, and indeed other receptors. This distinctive structure has led to numerous efforts to discover drugs against GPCRs with targeted therapeutic uses. Such "designer" drugs currently include allosteric regulators, inverse agonists, and drugs targeting hetero-oligomeric complexes. Moreover, the large family of orphan GPCRs provides a rich and novel field of targets to discover drugs with unique therapeutic properties. The numerous technologies to discover GPCR drugs have also greatly advanced over the years, facilitating compound screening against known and orphan GPCRs, as well as in the identification of unique designer GPCR drugs. Indeed, high throughput screening (HTS) technologies employing functional cell-based approaches are now widely used. These include measurement of second messenger accumulation such as cyclic AMP, calcium ions, and inositol phosphates, as well as mitogen-activated protein kinase activation, protein-protein interactions, and GPCR oligomerization. This review focuses on how the improved understanding of the molecular pharmacology of GPCRs, coupled with a plethora of novel HTS technologies, is leading to the discovery and development of an entirely new generation of GPCR-based therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998) · Nature · doi:10.1038/30666 · Cited by 2,134 · cited 2×
“140 Studies by McLatchie et al .”
Claing, A. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00023-5 · Cited by 519
Peptide-binding G protein-coupled receptors: new opportunities for drug design
Gurrath, M. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013371798 · Cited by 57 · cited 2×
“10 For example, the (cid:5) -opiate receptor is a target for the biological actions of the endogenous peptides enkephalin and (cid”
Cited by
Teaching old receptors new tricks: biasing seven-transmembrane receptors
Rajagopal, S., Rajagopal, K., & Lefkowitz, R. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3024 · Cited by 825
PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome
Kroeze, W. K., Sassano, M. F., Huang, X.-P., Lansu, K., McCorvy, J. D., Giguère, P. M., Sciaky, N., & Roth, B. L. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3014 · Cited by 755
High-throughput screening assays for the identification of chemical probes
Inglese, J., Johnson, R. L., Simeonov, A., Xia, M., Zheng, W., Austin, C. P., & Auld, D. S. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.17 · Cited by 614
Quantifying Ligand Bias at Seven-Transmembrane Receptors
Rajagopal, S., Ahn, S., Rominger, D. H., Gowen-MacDonald, W., Lam, C. M., DeWire, S. M., Violin, J. D., & Lefkowitz, R. J. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.072801 · Cited by 388
G protein‐coupled receptor hetero‐dimerization: contribution to pharmacology and function
Milligan, G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00169.x · Cited by 325
Metadata
- Authors
- Eglen, R. M., Bosse, R., & Reisine, T.
- Venue
- ASSAY and Drug Development Technologies
- Publisher
- SAGE Publications
- Published
- 2007-06
- Volume
- 5
- Issue
- 3
- Pages
- 425-452
- ISSN
- 1540-658X (ISSN-L)
- 1557-8127
- OpenAlex
- W2011964198
- Cited by
- 90
- References
- 3
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.